Current Report Filing (8-k)
September 11 2017 - 04:07PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of report (Date of earliest event reported):
September 11, 2017
ADVAXIS,
INC.
(Exact
Name of Registrant as Specified in Charter)
Delaware
|
|
000-28489
|
|
02-0563870
|
(State
or Other Jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
of
Incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
305
College Road East
Princeton,
New Jersey, 08540
(Address
of Principal Executive Offices)
(609)
452-9813
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act.
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act.
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2b under the Exchange Act.
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act.
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.[ ]
Item
2.02.
|
Results
of Operations and Financial Condition.
|
On
September 11, 2017, Advaxis, Inc. (“Advaxis” or the “Company”) issued a press release announcing results
of operations for the third quarter ended July 31, 2017 and providing a business update. A copy of such press release is being
furnished as Exhibit 99.1.
Item
9.01
|
Financial
Statements And Exhibits.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Advaxis,
Inc.
|
|
(Registrant)
|
|
|
|
Date:
September 11, 2017
|
|
|
|
|
|
|
By:
|
/s/
Sara M. Bonstein
|
|
|
Sara
M. Bonstein
|
|
|
Executive
Vice President and Chief Financial Officer
|
INDEX
TO EXHIBITS
Ayala Pharmaceuticals (QX) (USOTC:ADXS)
Historical Stock Chart
From Feb 2024 to Mar 2024
Ayala Pharmaceuticals (QX) (USOTC:ADXS)
Historical Stock Chart
From Mar 2023 to Mar 2024